Intercept Pharmaceuticals Inc., is a clinical stage biopharmaceutical company developing therapeutics for the treatment of chronic fibrotic and metabolic diseases.
Current News
  • August 9, 2011 - Intercept Pharmaceuticals and Servier Announce Agreement for Intercept's TGR5 Research Program in Type 2 Diabetes...More »


  • March 31, 2011 - Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis...More »


  • March 30, 2011 - Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease...More »


  • March 29, 2011 - Initiation of FLINT Announced by NIDDK: Study of Intercept Pharmaceuticals Obeticholic Acid (INT-747) in NASH...More »


Upcoming Events
  • November 6, 2011 - Intercept Pharmaceuticals, Inc.'s collaborator, Rachel McMahan, PhD of University of Colorado, CO, will present "Bile-Acid Receptor Activation Shifts Hepatic Monocytes/Macrophages Towards an Anti-Inflammatory Phenotype and Improves Non-Alcoholic Fatty Liver Disease" at the Annual Meeting of the American Association For The Study Of Liver Diseases held in San Francisco, CA during Parallel Session 8 on Sunday, Nov. 6, 4:00 pm PST, Room 2002-2004


  • November 7, 2011 - Intercept Pharmaceuticals, Inc.'s collaborator, Kris Kowdley MD, Director, Center for Liver Disease at the Virginia Mason Medical Center, will present "The First New Monotherapy Therapeutic PBC Study in a Decade? An International Study Evaluating the Farnesoid X Receptor Agonist Obeticholic Acid in PBC" at the Annual Meeting of the American Association For The Study Of Liver Diseases held in San Francisco, CA during the Presidential Plenary Session I on Monday, Nov. 7, 8:15 am to 8:30 am PST, Room 3000-3012.


  • November 7, 2011 - Intercept Pharmaceuticals, Inc.'s collaborator, Anna Baghdasaryan, MD, Medical University of Graz, Austria will present "FXR but not Tgr5 activation stimulates HCO3--rich bile secretion and ameliorates liver damage in Mdr2-/- (Abcb4-/-) mouse model of chronic liver injury" at the Annual Meeting of the American Association For The Study Of Liver Diseases held in San Francisco, CA during Parallel Session 19 on Monday, Nov. 7, 1:15 pm PST, Room 2011.


  • November 7, 2011 - Intercept Pharmaceuticals, Inc.'s collaborator , Gideon Hirschfield, MD PhD from the University of Toronto, will present "A Long Term Safety Extension Trial of the Farnesoid X Receptor (FXR) Agonist Obeticholic Acid (OCA) and UDCA in Primary Biliary Cirrhosis (PBC)" at the Annual Meeting of the American Association For The Study Of Liver Diseases held in San Francisco, CA during Parallel 20: Autoimmune and Cholestatic Liver Disease on Monday Nov. 7, 3:30 pm to 3:45 pm PST, Room 2011.